Eisai

News

Uptake of Leqembi for Alzheimer’s may be slow

Full FDA approval of Eisai and Biogen’s Alzheimer’s disease therapy Leqembi may have unlocked the door to a broader rollout of the drug and potentially blockbuster sales,

News

UK pilot will seek digital dimension to dementia management

A new two-year research collaboration in the UK will attempt to develop digital tools that could be used alongside approved therapies for people with dementia.

News

CMS sheds light on its registry plan for Alzheimer’s drugs

The Centers for Medicare and Medicaid Services (CMS) in the US has provided more details about the controversial plan to require participation in a patient registry as a c

Oncology

ASCO 2023 – Corina Dutcus

At ASCO 2023 last week in Chicago, editor-in-chief Jonah Comstock caught up with Dr Corina Dutcus, SVP clinical development at Eisai US, to talk about the CLEAR trial, one of Eisai’s major

News

FDA panel gives unanimous support to Leqembi

The first full regulatory approval for an amyloid-targeting therapy for Alzheimer’s disease could come within a month, after an expert panel voted 6 to 0 in favour of Eisa

News

Eisai files Leqembi in Korea, as US prospects firm up

Eisai has filed for approval of its Alzheimer’s disease therapy Leqembi in South Korea, just ahead of an FDA advisory committee meeting that has raised confidence that the

Uptake of Leqembi for Alzheimer’s may be slow

UK pilot will seek digital dimension to dementia management

CMS sheds light on its registry plan for Alzheimer’s drugs

ASCO 2023 – Corina Dutcus

FDA panel gives unanimous support to Leqembi

Eisai files Leqembi in Korea, as US prospects firm up

Protego's $130m for amyloidosis drug, and other financings

How to meet your physicians where they are online

Eisai

Editor's Picks